Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856244 | PMC |
| http://dx.doi.org/10.1136/gut.2005.078378 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Specialty laboratory testing for chronic abdominal pain in irritable bowel syndrome.
Scand J Gastroenterol
January 2025
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder seen by both primary care providers (PCPs) and gastroenterologists, and further diagnostic testing is generally discouraged unless red-flag symptoms are present.
Aims: Examine if advanced serologic testing for chronic abdominal pain in IBS patients followed society-specific guidelines and evaluate the diagnostic accuracy of these tests.
Methods: The study involved a retrospective cross-sectional analysis of adults aged 18 and older who were seen at our institution between 2013 and 2018.
A case report of long-latency evoked diaphragm potentials after exposure to acute intermittent hypoxia in post-West Nile virus meningoencephalitis.
J Neurophysiol
February 2025
Breathing Research and Therapeutics Center, Department of Physical Therapy, University of Florida, Gainesville, Florida, United States.
We present a case report of a 42-year-old female with post-West Nile virus meningoencephalitis who exhibited unique, long-latency diaphragm potentials evoked by transcranial and cervical magnetic stimulation after exposure to acute intermittent hypoxia (AIH). The subject was recruited for a study investigating AIH effects on respiratory motor function in healthy individuals. She had contracted West Nile virus infection 5 years before assessment that resulted in hospitalization and persistent allodynia but was not reported to the research team.
View Article and Find Full Text PDFGlycoprotein 350-targeted chimeric antigen receptor T-cell therapy for nonneoplastic chronic active Epstein-Barr virus infection: a case report.
Transl Pediatr
December 2024
Department of Infectious Diseases, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Chronic active Epstein-Barr virus (CAEBV) infection is a rare disease in which the Epstein-Barr virus (EBV) persists and replicates, causing chronic symptoms and fatal complications. The treatment of CAEBV is still evolving. Our case report showed a new therapy for CAEBV.
View Article and Find Full Text PDFFever of Unknown Origin: A Rare Presentation of Parathyroid Carcinoma.
Cureus
December 2024
General Medicine, All India Institute of Medical Sciences, Nagpur, Nagpur, IND.
Fever of unknown origin (FUO) can be a common manifestation of multiple disease processes like infections, hematological & solid organ malignancies, autoimmune disorders, and autoinflammatory diseases. Endocrine causes of FUO are rare but should be considered in differential diagnosis. We present a case of a 35-year-old female with prolonged on-and-off fever and intermittent vomiting for nine months, where extensive workups for chronic infections, malignancy, and autoimmune conditions initially yielded no definitive diagnosis.
View Article and Find Full Text PDFIntratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
JAMA Oncol
January 2025
Department of Surgery, University of California, San Francisco.
Importance: Intratumoral immunotherapy that leverages the biological characteristics of high-risk ductal carcinoma in situ (DCIS) may be able to reduce the extent of surgical treatment and provide an alternative approach to improve patient outcomes.
Objective: To determine if combination intratumoral immunotherapy can activate immune cells to shrink or eliminate high-risk DCIS.
Design, Setting, And Participants: This phase 1 open-label nonrandomized clinical trial at a single academic center tested the safety and efficacy of intratumoral immunotherapy in patients with high-risk DCIS, defined as at least 2 of the following present: younger than 45 years, tumor size greater than 5 cm, high-grade, palpable mass, hormone receptor (HR)-negative, or ERBB2-positive.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!